Time For Companion Diagnostics Guidance From FDA Is Now, PMC Says
Industry groups, representing drug makers, test manufacturers, labs and others, are redoubling the pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments
You may also be interested in...
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011